Company:  CYTRX CORP (CYTR)
Form Type:  10-K
Filing Date:  3/13/2012 
CIK:  0000799698 
Address:  11726 SAN VICENTE BOULEVARD
SUITE 650
 
City, State, Zip:  LOS ANGELES, California 90049 
Telephone:  310-826-5648 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$3.18  
Change: 
0.035 (1.11%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$176.69M
Description of Business
References in this Annual Report to the �company,� �we,� �us� or �our� refer to CytRx Corporation, unless otherwise indicated. COMPANY OVERVIEW We are a biopharmaceutical research and development company specializing in oncology. We currently are focused on the clinical development of aldoxorubicin (formerly known as INNO-206), our modified version of the widely-used chemotherapeutic agent, doxorubicin. We recently reported top-line efficacy results (median progression-free survival, progression-free survival at six months, overall response rates and hazard ratios) of our Phase 2b clinical trial with aldoxorubicin as a treatment for soft tissue sarcoma, or STS. Hazard ratios - the likelihood that the study endpoint (in this case tumor progression) will be reached during a given period - are an important measure of the reliability and uniformity of the absolute data for progression-free survival, or PFS.
Register for EDGAR Pro and access this filing in:     
  FORM 10-K
    PART I
      Item 1. BUSINESS
      Item 1A. RISK FACTORS
      Item 1B. UNRESOLVED STAFF COMMENTS
      Item 2. PROPERTIES
      Item 3. LEGAL PROCEEDINGS
      Item 4. MINE SAFETY DISCLOSURES
    PART II
      Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED ...
      Item 6. SELECTED FINANCIAL DATA
      Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
        Liquidity and Capital Resources
        Results of Operations
      Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
      Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ...
      Item 9A. CONTROLS AND PROCEDURES
      Item 9B. OTHER INFORMATION
    PART III
      Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
        NAME AND TITLE
      Item 11. EXECUTIVE COMPENSATION
        COMPENSATION TABLE
        OPTIONS
      Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND ...
        BENEFICIAL OWNERS
      Item 13. CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND ...
      Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
    PART IV
      Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
    Notes to Consolidated Financial Statements
    Reports of Independent Registered Public Accounting Firms
    SIGNATURES
    BALANCE SHEET
    INCOME STATEMENT
    STOCKHOLDERS EQUITY
    CASH FLOW
    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
    BALANCE SHEET
  EXHIBIT 3.1
    RESTATED CERTIFICATE OF INCORPORATION OF
  EXHIBIT 10.6
  EXHIBIT 10.12
  EXHIBIT 10.20
  EXHIBIT 10.21
  EXHIBIT 10.22
  EXHIBIT 10.23
  EXHIBIT 10.24
  EXHIBIT 10.26
  EXHIBIT 23.1
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 31.1
    CERTIFICATIONS
  EXHIBIT 31.2
    CERTIFICATIONS
  EXHIBIT 32.1
  EXHIBIT 32.2
BROKERAGE PARTNERS